Literature DB >> 2879626

Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

M P Goren, R K Wright, M E Horowitz, C B Pratt.   

Abstract

We monitored acute tubular damage in 16 patients who received a 5-day course of ifosfamide (1.6 g/m2/day) and mesna (1.2 g/m2/day) therapy. Urinary concentrations of alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase, and total protein increased in every patient, but the extent of tubular toxicity varied widely among patients. Evidence of toxicity was greatest in patients whose tumors involved the kidneys. The time course of enzymuria and proteinuria indicated tubular cell necrosis. We observed this acute toxic effect despite the administration of sufficient mesna to prevent hemorrhagic cystitis. Urinary marker concentrations returned towards pre-dose levels, and there were no increases in serum creatinine concentrations measured 3 weeks after treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2879626

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  22 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Iphosphamide-induced nephrotoxicity in children.

Authors:  R Shore; M Greenberg; D Geary; G Koren
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

Review 3.  A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.

Authors:  Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Karen Wasilewski-Masker; Louis S Constine; Leslie L Robison; Kirsten K Ness
Journal:  Curr Pediatr Rev       Date:  2014

4.  Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.

Authors:  M P Goren; C B Pratt; M J Viar
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Cytostatics--induced tubular toxicity.

Authors:  M Brandis; K von der Hardt; R B Zimmerhackl; M Mohrmann; J Leititis
Journal:  Clin Investig       Date:  1993-10

6.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

7.  Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Amal Q Darweesh; Amal J Fatani
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

8.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Experience with ifosfamide in paediatric tumours.

Authors:  J de Kraker; P A Voûte
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.

Authors:  A D Elias; L J Ayash; J P Eder; C Wheeler; J Deary; L Weissman; M Hunt; J Critchlow; L Schnipper; E Frei
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.